‘Inherently implausible’: Generic Partners loses fight with Neurim over melatonin drug patent

Intellectual Property 2022-01-20 2:59 pm By Cindy Cameronne | Sydney

Israeli drug company Neurim Pharmaceuticals has won an eight month extension to apply for a grace period for its melatonin tablet patent to treat children with autism spectrum disorder after Australian company Generic Partners lost its “inherently implausible” opposition to the patent.